Immunogenicity of single-dose Vero cell-derived Japanese encephalitis vaccine in Japanese adults |
| |
| Affiliation: | 1. Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan;2. Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan;3. Department of Infection Control and Prevention, Tokyo Medical University, Japan;4. Department of Clinical Research and Informatics, International Clinical Research Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan;5. Department of Infection Control and Laboratory Diagnostics, Internal Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan;1. Department of Infection Control and Prevention, Kitasato University Hospital, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0375, Japan;2. Department of General Medicine, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0374, Japan;3. Department of Infection Control and Laboratory Diagnostics, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai 980-8574, Japan;4. Department of Virology, Kitasato Research Center for Environmental Science, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0329, Japan;5. Department of Microbiology and Immunology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan;6. Department of Microbiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0374, Japan;7. Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0374, Japan;1. Department of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan;2. Department of Infection Control and Laboratory Diagnostics, Internal Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan;3. Department of Clinical Laboratory, Miyagi Medical Association Health Center, Sendai, Japan;1. Department of Infection Control and Laboratory Diagnostics, Internal Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan;2. Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, USA;3. Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan;4. Department of Cardiovascular Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan;5. Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan;1. GE Healthcare Bio-Sciences AB, Björkgatan 30, SE-751 84 Uppsala, Sweden;2. Isconova, Kungsgatan 109, SE-753 18 Uppsala, Sweden;1. Division of Viral Products, CBER, FDA, Silver Spring, MD 20993, USA;2. Novavax, Gaithersburg, MD 20878, USA |
| |
| Abstract: | In Japan, intensive immunization against Japanese encephalitis (JE) was performed from 1967 to 1976, and regular JE immunization was performed thereafter. However, for Japanese adults facing JE risk, dates of vaccination with new inactivated Vero cell-derived JE vaccine are unavailable. This study investigated how a single dose of Vero cell-derived JE vaccine affects Japanese adults. Neutralizing antibodies were measured pre- and post-JE vaccination in 79 participants (age 40.7 ± 9.4 years), enrolled between October 2009 and March 2011, whose JE-vaccination data were gathered from vaccination records and history taking. Before vaccination, the participants' seroprotection rate (SPR) was 51.9%, whereas SPR after vaccination was 93.7%. The seroconversion rate (SCR), which measures seronegative cases that turn seropositive after vaccination, was 86.8%. The geometric mean titer (GMT) was 14.7 before vaccination and 70.1 after vaccination. Age was a significant difference between seroprotected (42.8 years) and non-seroprotected (38.7 years) groups before vaccination. Then the difference of age, SCR, pre-vaccination GMT, post-vaccination GMT and sex ratio were also significant in participants aged 25–39 years and ≥40 years, who represent generations born when Japan's JE-vaccination policy changed. SCR was 100% in participants aged 25–39 years with a vaccination recorded 55.6% in participants aged 25–39 without a vaccination record, and 96.0% in participants aged ≥40 years. Thus, more participants aged 25–39 years were seroprotected before vaccination, but SCR was higher in those aged ≥40 years. Most Japanese adults can be protected after one-dose vaccination, but this may be insufficient for people aged 25–39 years without recorded JE vaccination. |
| |
| Keywords: | Japanese encephalitis Vero cells Japanese Travel vaccine |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
